The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 1, 2014, Pages 7-21

  Esteves, A R ^a   Gozes, I ^b   Cardoso, S M ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Microtubule network; Mitochondria dynamics; NAP

Indexed keywords

ALPHA SYNUCLEIN; DAVUNETIDE; OLIGOMER;

ADULT; ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN MITOCHONDRION; CELL DAMAGE; CELL FUSION; CELL MIGRATION; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; HOMEOSTASIS; HUMAN; HUMAN CELL; LYSOSOME; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; UBIQUITINATION;

(CONTROL CYBRIDS); (SPORADIC PARKINSON'S DISEASE CYBRIDS); 1-METHYL-4-PHENYLPYRIDINIUM; ALPHA-SYNUCLEIN; ASYN; CT CYBRIDS; MICROTUBULE NETWORK; MITOCHONDRIA DYNAMICS; MITOCHONDRIAL DNA; MPP(+); MTDNA; NAP; PARKINSON'S DISEASE; PD; SPD CYBRIDS;

AGED; ALPHA-SYNUCLEIN; AUTOPHAGY; CASE-CONTROL STUDIES; CELL LINE; FEMALE; HUMANS; LYSOSOMES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROTUBULES; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PARKINSON DISEASE; UBIQUITINATION; VACUOLES;

EID: 84887706170     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.10.003     Document Type: Article

References (112)

1. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
2. Parker W.D., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26:719-723.
3. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
4. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 2006, 26:5256-5264.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
6. Lach B., Grimes D., Benoit B., Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol. 1992, 83:352-360.
7. Bertrand E., Lechowicz W., Lewandowska E., Szpak G.M., Dymecki J., Kosno-Kruszewska E., Wierzba-Bobrowicz T. Degenerative axonal changes in the hippocampus and amygdala in Parkinson's disease. Folia Neuropathol. 2003, 41:197-207.
8. Arduino D.M., Esteves A.R., Oliveira C.R., Cardoso S.M. Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2010, 9:105-119.
9. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 2004, 279:4625-4631.
10. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp. Neurol. 2008, 209:5-11.
11. Kim H.Y., Cho M.K., Kumar A., Maier E., Siebenhaar C., Becker S., Fernandez C.O., Lashuel H.A., Benz R., Lange A., Zweckstetter M. Structural properties of pore-forming oligomers of alpha-synuclein. J. Am. Chem. Soc. 2009, 131:17482-17489.
12. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
13. Morris R.L., Hollenbeck P.J. Axonal transport of mitochondria along microtubules and F-actin in living vertebrate neurons. J. Cell Biol. 1995, 131:1315-1326.
14. Ligon L.A., Steward O. Role of microtubules and actin filaments in the movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. J. Comp. Neurol. 2000, 427:351-361.
15. Lee H.J., Khoshaghideh F., Lee S., Lee S.J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 2006, 24:3153-3162.
16. Schiavo G., Fainzilber M. Cell biology: alternative energy for neuronal motors. Nature 2013, 495:178-180.
17. Zala D., Hinckelmann M.V., Yu H., Lyra da Cunha M.M., Liot G., Cordelieres F.P., Marco S., Saudou F. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 2013, 152:479-491.
18. Esteves A.R., Domingues A.F., Ferreira I.L., Januario C., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 2008, 8:219-228.
19. Esteves A.R., Arduino D.M., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Oxidative stress involvement in alpha-synuclein oligomerization in Parkinson's disease cybrids. Antioxid. Redox Signal. 2009, 11:439-448.
20. Esteves A.R., Lu J., Rodova M., Onyango I., Lezi E., Dubinsky R., Lyons K.E., Pahwa R., Burns J.M., Cardoso S.M., Swerdlow R.H. Mitochondrial respiration and respiration-associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J. Neurochem. 2010, 113:674-682.
21. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett J.P., Davis R.E., Parker W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 1996, 40:663-671.
22. Esteves A.R., Arduino D.M., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Microtubule depolymerization potentiates alpha-synuclein oligomerization. Front. Aging Neurosci. 2010, 1:5.
23. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J. Clin. Oncol. 2006, 24:1633-1642.
24. Michaelis M.L., Georg G., Telikepalli H., McIntosh M., Rajewski R.A. Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. Curr. Alzheimer Res. 2006, 3:215-219.
25. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 1999, 72:1283-1293.
26. Zamostiano R., Pinhasov A., Gelber E., Steingart R.A., Seroussi E., Giladi E., Bassan M., Wollman Y., Eyre H.J., Mulley J.C., Brenneman D.E., Gozes I. Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 2001, 276:708-714.
27. Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol. Ther. 2007, 114:146-154.
28. Divinski I., Mittelman L., Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 2004, 279:28531-28538.
29. Gozes I., Divinski I. The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J. Alzheimers Dis. 2004, 6:S37-S41.
30. Divinski I., Holtser-Cochav M., Vulih-Schultzman I., Steingart R.A., Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 2006, 98:973-984.
31. Litvan I. Update on epidemiological aspects of progressive supranuclear palsy. Mov. Disord. 2003, 18(Suppl. 6):S43-S50.
32. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 1992, 32:782-788.
33. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
34. Sodja C., Fang H., Dasgupta T., Ribecco M., Walker P.R., Sikorska M. Identification of functional dopamine receptors in human teratocarcinoma NT2 cells. Brain Res. Mol. Brain Res. 2002, 99:83-91.
35. Misiuta I.E., Saporta S., Sanberg P.R., Zigova T., Willing A.E. Influence of retinoic acid and lithium on proliferation and dopaminergic potential of human NT2 cells. J. Neurosci. Res. 2006, 83:668-679.
36. Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P., Davis R.E., Parker W.D. Cybrids in Alzheimer's disease: a cellular model of the disease?. Neurology 1997, 49:918-925.
37. Binder D.R., Dunn W.H., Swerdlow R.H. Molecular characterization of mtDNA depleted and repleted NT2 cell lines. Mitochondrion 2005, 5:255-265.
38. Cardoso S.M., Rego A.C., Penacho N., Oliveira C.R. Apoptotic cell death induced by hydrogen peroxide in NT2 parental and mitochondrial DNA depleted cells. Neurochem. Int. 2004, 45:693-698.
39. Miller S.W., Trimmer P.A., Parker W.D., Davis R.E. Creation and characterization of mitochondrial DNA-depleted cell lines with "neuronal-like" properties. J. Neurochem. 1996, 67:1897-1907.
40. Arduino D.M., Esteves A.R., Cortes L., Silva D.F., Patel B., Grazina M., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum. Mol. Genet. 2012, 21:4680-4702.
41. Yu A.C., Fisher T.E., Hertz E., Tildon J.T., Schousboe A., Hertz L. Metabolic fate of [14C]-glutamine in mouse cerebral neurons in primary cultures. J. Neurosci. Res. 1984, 11:351-357.
42. Resende R., Ferreiro E., Pereira C., Oliveira C.R. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J. Neurosci. Res. 2008, 86:2091-2099.
43. Joshi H.C., Cleveland D.W. Differential utilization of beta-tubulin isotypes in differentiating neurites. J. Cell Biol. 1989, 109:663-673.
44. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18670-18675.
45. Dagda R.K., Cherra S.J., Kulich S.M., Tandon A., Park D., Chu C.T. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
46. Bolte S., Cordelieres F.P. A guided tour into subcellular colocalization analysis in light microscopy. J. Microsc. 2006, 224:213-232.
47. Janke C., Bulinski J.C. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat. Rev. Mol. Cell Biol. 2011, 12:773-786.
48. Gozes I., Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr. Alzheimer Res. 2007, 4:507-509.
49. MacAskill A.F., Kittler J.T. Control of mitochondrial transport and localization in neurons. Trends Cell Biol. 2010, 20:102-112.
50. Esteves A.R., Arduino D.M., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. Neurobiol. Dis. 2010, 37:723-730.
51. Fass E., Shvets E., Degani I., Hirschberg K., Elazar Z. Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. J. Biol. Chem. 2006, 281:36303-36316.
52. Kochl R., Hu X.W., Chan E.Y., Tooze S.A. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006, 7:129-145.
53. Bains M., Heidenreich K.A. Live-cell imaging of autophagy induction and autophagosome-lysosome fusion in primary cultured neurons. Methods Enzymol. 2009, 453:145-158.
54. Li W., Hoffman P.N., Stirling W., Price D.L., Lee M.K. Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J. Neurochem. 2004, 88:401-410.
55. Saha A.R., Hill J., Utton M.A., Asuni A.A., Ackerley S., Grierson A.J., Miller C.C., Davies A.M., Buchman V.L., Anderton B.H., Hanger D.P. Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 2004, 117:1017-1024.
56. Parone P.A., Da Cruz S., Tondera D., Mattenberger Y., James D.I., Maechler P., Barja F., Martinou J.C. Preventing mitochondrial fission impairs mitochondrial function and leads to loss of mitochondrial DNA. PLoS One 2008, 3:e3257.
57. Mopert K., Hajek P., Frank S., Chen C., Kaufmann J., Santel A. Loss of Drp1 function alters OPA1 processing and changes mitochondrial membrane organization. Exp. Cell Res. 2009, 315:2165-2180.
58. Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C.A., Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010, 189:211-221.
59. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8:e1000298.
60. Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R.L., Kim J., May J., Tocilescu M.A., Liu W., Ko H.S., Magrane J., Moore D.J., Dawson V.L., Grailhe R., Dawson T.M., Li C., Tieu K., Przedborski S. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:378-383.
61. Chan N.C., Salazar A.M., Pham A.H., Sweredoski M.J., Kolawa N.J., Graham R.L., Hess S., Chan D.C. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. 2011, 20:1726-1737.
62. Grey J.Y., Connor M.K., Gordon J.W., Yano M., Mori M., Hood D.A. Tom20-mediated mitochondrial protein import in muscle cells during differentiation. Am. J. Physiol. Cell Physiol. 2000, 279:C1393-C1400.
63. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
64. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
65. Narendra D., Kane L.A., Hauser D.N., Fearnley I.M., Youle R.J. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 2010, 6:1090-1106.
66. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283:9089-9100.
67. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65:1272-1284.
68. Chinta S.J., Mallajosyula J.K., Rane A., Andersen J.K. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci. Lett. 2010, 486:235-239.
69. + toxicity in mitochondrial DNA depleted cells. Neurotox. Res. 2008, 13:31-38.
70. +-induced neurodegeneration. J. Neurochem. 2010, 115:247-258.
71. Cardoso S.M. The mitochondrial cascade hypothesis for Parkinson's disease. Curr. Pharm. Des. 2011, 17:3390-3397.
72. + affects microtubule dynamics by acting as a destabilising factor. FEBS Lett. 2005, 579:4781-4786.
73. Morfini G., Pigino G., Opalach K., Serulle Y., Moreira J.E., Sugimori M., Llinas R.R., Brady S.T. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2442-2447.
74. Ren Y., Feng J. Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J. Neurochem. 2007, 103:303-311.
75. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A.M., Servoss S.J., Brenneman D.E., Gozes I. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 2003, 144:83-90.
76. Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., Holser-Cochav M., Vered K., Newton P., Aisen P.S., Matsuoka Y., van Dyck C.H., Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11:353-368.
77. Gozes I., Steingart R.A., Spier A.D. NAP mechanisms of neuroprotection. J. Mol. Neurosci. 2004, 24:67-72.
78. Zhang B., Carroll J., Trojanowski J.Q., Yao Y., Iba M., Potuzak J.S., Hogan A.M., Xie S.X., Ballatore C., Smith A.B., Lee V.M., Brunden K.R. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 2012, 32:3601-3611.
79. Cartelli D., Casagrande F., Busceti C.L., Bucci D., Molinaro G., Traficante A., Passarella D., Giavini E., Pezzoli G., Battaglia G., Cappelletti G. Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. Sci. Rep. 2013, 3:1837.
80. Gozes I., Divinsky I., Pilzer I., Fridkin M., Brenneman D.E., Spier A.D. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 2003, 20:315-322.
81. Leker R.R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M., Giladi E., Romano J., Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke 2002, 33:1085-1092.
82. Jehle T., Dimitriu C., Auer S., Knoth R., Vidal-Sanz M., Gozes I., Lagreze W.A. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1255-1263.
83. Idan-Feldman A., Schirer Y., Polyzoidou E., Touloumi O., Lagoudaki R., Grigoriadis N.C., Gozes I. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol. Dis. 2011, 44:327-339.
84. Ashur-Fabian O., Segal-Ruder Y., Skutelsky E., Brenneman D.E., Steingart R.A., Giladi E., Gozes I. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 2003, 24:1413-1423.
85. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., LaFerla F.M., Gozes I., Aisen P.S. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 2007, 31:165-170.
86. Gozes I., Divinski I., Piltzer I. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci. 2008, 9(Suppl. 3):S3.
87. Shiryaev N., Jouroukhin Y., Giladi E., Polyzoidou E., Grigoriadis N.C., Rosenmann H., Gozes I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol. Dis. 2009, 34:381-388.
88. Fleming S.M., Mulligan C.K., Richter F., Mortazavi F., Lemesre V., Frias C., Zhu C., Stewart A., Gozes I., Morimoto B., Chesselet M.F. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol. Cell. Neurosci. 2011, 46:597-606.
89. Zemlyak I., Sapolsky R., Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur. J. Pharmacol. 2009, 618:9-14.
90. Cambray-Deakin M.A., Burgoyne R.D. Acetylated and detyrosinated alpha-tubulins are co-localized in stable microtubules in rat meningeal fibroblasts. Cell Motil. Cytoskeleton 1987, 8:284-291.
91. Cambray-Deakin M.A., Burgoyne R.D. Posttranslational modifications of alpha-tubulin: acetylated and detyrosinated forms in axons of rat cerebellum. J. Cell Biol. 1987, 104:1569-1574.
92. Bulinski J.C. Microtubule modification: acetylation speeds anterograde traffic flow. Curr. Biol. 2007, 17:R18-R20.
93. Dompierre J.P., Godin J.D., Charrin B.C., Cordelieres F.P., King S.J., Humbert S., Saudou F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 2007, 27:3571-3583.
94. Xie R., Nguyen S., McKeehan W.L., Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol. 2010, 11:89.
95. Yang Y., Feng L.Q., Zheng X.X. Microtubule and kinesin/dynein-dependent, bi-directional transport of autolysosomes in neurites of PC12 cells. Int. J. Biochem. Cell Biol. 2011, 43:1147-1156.
96. Liu L., Xie R., Nguyen S., Ye M., McKeehan W.L. Robust autophagy/mitophagy persists during mitosis. Cell Cycle 2009, 8:1616-1620.
97. Santos D., Cardoso S.M. Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion 2012, 12:428-437.
98. de Brito O.M., Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456:605-610.
99. Hailey D.W., Rambold A.S., Satpute-Krishnan P., Mitra K., Sougrat R., Kim P.K., Lippincott-Schwartz J. Mitochondria supply membranes for autophagosome biogenesis during starvation. Cell 2010, 141:656-667.
100. Gomes L.C., Di Benedetto G., Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. Nat. Cell Biol. 2011, 13:589-598.
101. Stowers R.S., Megeath L.J., Gorska-Andrzejak J., Meinertzhagen I.A., Schwarz T.L. Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila protein. Neuron 2002, 36:1063-1077.
102. Glater E.E., Megeath L.J., Stowers R.S., Schwarz T.L. Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent. J. Cell Biol. 2006, 173:545-557.
103. Webb J.L., Ravikumar B., Atkins J., Skepper J.N., Rubinsztein D.C. Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 2003, 278:25009-25013.
104. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
105. Martinez-Vicente M., Talloczy Z., Kaushik S., Massey A.C., Mazzulli J., Mosharov E.V., Hodara R., Fredenburg R., Wu D.C., Follenzi A., Dauer W., Przedborski S., Ischiropoulos H., Lansbury P.T., Sulzer D., Cuervo A.M. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 2008, 118:777-788.
106. Zhang N.Y., Tang Z., Liu C.W. Alpha-synuclein protofibrils inhibit 26S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. J. Biol. Chem. 2008, 283:20288-20298.
107. Emmanouilidou E., Stefanis L., Vekrellis K. Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 2010, 31:953-968.
108. Utton M.A., Noble W.J., Hill J.E., Anderton B.H., Hanger D.P. Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J. Cell Sci. 2005, 118:4645-4654.
109. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
110. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275:18344-18349.
111. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 2001, 21:8053-8061.
112. Ries V., Oertel W.H., Hoglinger G.U. Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy. J. Mol. Neurosci. 2011, 45:684-689.